Gastric bypass may change how your body absorbs prozac

NCT ID NCT03476525

Recruiting now Knowledge-focused Sponsor: Norwegian University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study looks at how two common weight-loss surgeries — gastric bypass and sleeve gastrectomy — change the way the body processes the antidepressant fluoxetine (Prozac). Researchers will measure drug levels in the blood of 12 participants before and after surgery. The goal is to understand whether surgery alters how much medication reaches the bloodstream, which could help doctors adjust doses for better treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fluoxetine (Prozac)
What this could lead to: If successful, this study could help doctors adjust antidepressant doses after bariatric surgery to ensure patients get the right amount of medication.
What could go wrong: This is a small, early-stage study with only 12 participants, so results may not apply to everyone. The study measures drug levels in blood, not actual treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

morbid obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY, MORBID

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

St. Olavs University Hospital
RECRUITING

Trondheim, Norway

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.